Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 9:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluticasone / Salmeterol Clear all
Completed Phase 3 Interventional Results available

MGR001 / Advair Diskus Local Equivalence Study in Asthma

NCT02245672
View directory record Official record
Conditions
Asthma
Interventions
MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Mylan Pharma UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

NCT01772147
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
12 Years and older
Enrollment
1,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 18, 2026, 9:35 AM EDT
Terminated Phase 4 Interventional

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

NCT00346749
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 4 Interventional

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

NCT00118690
View directory record Official record
Conditions
Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions
Fluticasone propionate/salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 17 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
51
States / cities
Jonesboro, Arkansas • East Artesia, California • Huntington Beach, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 18, 2026, 9:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

NCT00568347
View directory record Official record
Conditions
COPD
Interventions
fluticasone 100mcg/ salmeterol 50mcg, fluticasone 250/salmeterol 50, Salmeterol, salmeterol and fluticasone propionate
Drug
Lead sponsor
Arthur F Gelb MD
Individual
Eligibility
20 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 2 Interventional

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

NCT00403286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2009 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Results available

Long-acting Beta Agonist Step Down Study

NCT01437995
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone/Salmeterol Diskus, Fluticasone Diskus
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 18, 2026, 9:35 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Advair HFA in Healthy and HAPE Predisposed Subjects

NCT06040268
View directory record Official record
Conditions
Altitude Edema
Interventions
Advair HFA, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

NCT01772368
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, FS MDPI, Advair Diskus, Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 1 Interventional Results available

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

NCT02260492
View directory record Official record
Conditions
Asthma
Interventions
OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Oriel Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 18, 2026, 9:35 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 3 Interventional

Advair Pediatric Once-Daily

NCT00920959
View directory record Official record
Conditions
Asthma
Interventions
FP 100mcg, FSC 100/50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
141
States / cities
Ozark, Alabama • Tucson, Arizona • Little Rock, Arkansas + 118 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

NCT02175771
View directory record Official record
Conditions
Persistent Asthma
Interventions
Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Results available

The Effect on Depressive Symptoms in ECF Residents With COPD

NCT00974246
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Depression
Interventions
Advair diskus
Drug
Lead sponsor
Valley Medical Research
Other
Eligibility
18 Years to 94 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Brooksville, Florida • Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

NCT01312961
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
50
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

NCT03756883
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate and Salmeterol Inhalation Powder, Placebo Inhalation Powder
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

NCT02164539
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF, UMEC, VI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Newport Beach, California • San Diego, California • Upland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Results available

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

NCT00633217
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol DISKUS 250/50mcg, Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Jasper, Alabama • Mobile, Alabama • Lafayette, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Results available

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

NCT00452348
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
58
States / cities
Birmingham, Alabama • Mobile, Alabama • Fresno, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 18, 2026, 9:35 AM EDT
Completed Early Phase 1 Interventional

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

NCT02826343
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 18, 2026, 9:35 AM EDT